Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, Hilo, HI 96720, USA.
Department of Pediatric Oncology/Hematology, Sophia Children's Hospital, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands.
J Mol Biol. 2014 Jan 23;426(2):332-46. doi: 10.1016/j.jmb.2013.09.037. Epub 2013 Oct 1.
Ornithine decarboxylase (ODC) is the sentinel enzyme in polyamine biosynthesis. Both ODC and polyamines regulate cell division, proliferation, and apoptosis. Sepiapterin reductase (SPR) catalyzes the last step in the biosynthesis of tetrahydrobiopterin (BH4), an essential cofactor of nitric oxide synthase, and has been implicated in neurological diseases but not yet in cancer. In this study, we present compelling evidence that native ODC and SPR physically interact, and we defined the individual amino acid residues involved in both enzymes using in silico protein-protein docking simulations. The resulting heterocomplex is a surprisingly compact structure, featuring two energetically and structurally equivalent binding modes both in monomer and in dimer conformations. The novel interaction between ODC and SPR proteins was confirmed under physiological conditions by co-immunoprecipitation and co-localization in neuroblastoma (NB) cells. Importantly, we showed that siRNA (small interfering RNA)-mediated knockdown of SPR expression significantly reduced endogenous ODC enzyme activity in NB cells, thus demonstrating the biological relevance of the ODC-SPR interaction. Finally, in a cohort of 88 human NB tumors, we found that high SPR mRNA expression correlated significantly with poor survival prognosis using a Kaplan-Meier analysis (log-rank test, P=5 × 10(-4)), suggesting an oncogenic role for SPR in NB tumorigenesis. In conclusion, we showed that ODC binds SPR and thus propose a new concept in which two well-characterized biochemical pathways converge via the interaction of two enzymes. We identified SPR as a novel regulator of ODC enzyme activity and, based on clinical evidence, present a model in which SPR drives ODC-mediated malignant progression in NB.
鸟氨酸脱羧酶(ODC)是多胺生物合成中的关键酶。ODC 和多胺都调节细胞分裂、增殖和凋亡。蝶呤还原酶(SPR)催化四氢生物蝶呤(BH4)生物合成的最后一步,BH4 是一氧化氮合酶的必需辅因子,已被牵连到神经疾病中,但尚未涉及癌症。在这项研究中,我们提供了令人信服的证据表明,天然的 ODC 和 SPR 物理相互作用,我们使用计算机蛋白-蛋白对接模拟来定义两个酶涉及的个别氨基酸残基。所得的异源复合物是一个令人惊讶的紧凑结构,在单体和二聚体构象中都具有两种能量和结构等效的结合模式。在神经母细胞瘤(NB)细胞中,通过共免疫沉淀和共定位在生理条件下证实了 ODC 和 SPR 蛋白之间的新型相互作用。重要的是,我们表明,siRNA(小干扰 RNA)介导的 SPR 表达下调显著降低了 NB 细胞中内源性 ODC 酶活性,从而证明了 ODC-SPR 相互作用的生物学相关性。最后,在 88 个人类 NB 肿瘤的队列中,我们发现使用 Kaplan-Meier 分析(对数秩检验,P=5×10(-4)),高 SPR mRNA 表达与不良生存预后显著相关,表明 SPR 在 NB 肿瘤发生中具有致癌作用。总之,我们表明 ODC 与 SPR 结合,因此提出了一个新概念,即两个特征良好的生化途径通过两种酶的相互作用而汇聚。我们确定 SPR 是 ODC 酶活性的新调节剂,并基于临床证据提出了一个模型,其中 SPR 驱动 NB 中 ODC 介导的恶性进展。